Markets Earnings Screener Watchlist

Fundamentals and filings are sourced from SEC EDGAR. Market data, ownership and analyst consensus are sourced from Nasdaq. Written analysis is generated by metir from those sources and the linked reporting.

All information is provided for informational purposes only. It is not investment, financial, tax or legal advice, is not a recommendation to buy or sell any security, and is not intended for trading purposes. Data may be delayed or incomplete.

Markets open

Amgen Inc. Stock Price: Quote, Financials, Forecast & News (AMGN)

Amgen Inc.

AMGN · NASDAQ-GS

Overview Financials Earnings Holders Historical Data Analysis

$406.51+$16.494.23%

As of: Aug 5, 6:01 PM

Prev Close: $390.02
Market Cap: $219.40B
Open: —
Trailing P/E: —
Day Range: $416.22 - $391.00
52W Range: $398.00 - $269.77
Forward P/E: —
EPS: —
Volume: 3.16M
Dividend Yield: 2.58%

Notable Price Movement

Weekly movement commentary will appear here once it has been generated for this company.

Stories & Analysis

Amgen Q2 Net Income Improves; Repatha Sales Jump 37% ; Lifts 2026 Earnings Guidance

RTTNews · 12h ago

Amgen (AMGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks · 20h ago

Amgen (AMGN) Q2 Earnings and Revenues Surpass Estimates

Zacks · 21h ago

Amgen Inc. Profit Rises In Q2

RTTNews · 22h ago

Amgen Q2 26 Earnings Conference Call At 4:30 PM ET

RTTNews · 23h ago After-Hours Earnings Report for August 4, 2026 : AMD, ANET, AMGN, GILD, BKNG, EMR, SU, EOG, ALAB, DVN, PRU, CPNG

NASDAQ.com · 1d ago Dow Analyst Moves: AMGN

BNK Invest · 1d ago See How Amgen Ranks Among Analysts' Top Dow 30 Picks

BNK Invest · 1d ago

Symbol: AMGN
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: NASDAQ-GS

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions. Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes.

Analyst Consensus

Hold

24 analysts

$407

Current

—

Low

$370

Average

—

High

Average target implies -8.98% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Novo Nordisk A/SNVO · NYSE$44.841.25%
Abbott LaboratoriesABT · NYSE$104.540.87%
Gilead Sciences, Inc.GILD · Nasdaq$131.612.70%
Novartis AGNVS · NYSE$154.410.74%

Beta

—

Avg Volume

2.68M